CN110934911A - Application of roxburgh rose or extract thereof in preparation of medicine or health-care product for preventing and treating pulmonary fibrosis - Google Patents
Application of roxburgh rose or extract thereof in preparation of medicine or health-care product for preventing and treating pulmonary fibrosis Download PDFInfo
- Publication number
- CN110934911A CN110934911A CN201911308961.8A CN201911308961A CN110934911A CN 110934911 A CN110934911 A CN 110934911A CN 201911308961 A CN201911308961 A CN 201911308961A CN 110934911 A CN110934911 A CN 110934911A
- Authority
- CN
- China
- Prior art keywords
- pulmonary fibrosis
- roxburgh rose
- medicine
- use according
- health
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000005069 pulmonary fibrosis Diseases 0.000 title claims abstract description 48
- 241000220317 Rosa Species 0.000 title claims abstract description 35
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 230000036541 health Effects 0.000 claims abstract description 11
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 37
- 210000004072 lung Anatomy 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 210000002919 epithelial cell Anatomy 0.000 claims description 15
- 108010006654 Bleomycin Proteins 0.000 claims description 14
- 229960001561 bleomycin Drugs 0.000 claims description 14
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 14
- 210000001519 tissue Anatomy 0.000 claims description 13
- 210000002950 fibroblast Anatomy 0.000 claims description 12
- 230000035755 proliferation Effects 0.000 claims description 12
- 230000007705 epithelial mesenchymal transition Effects 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 206010016654 Fibrosis Diseases 0.000 claims description 8
- 230000004761 fibrosis Effects 0.000 claims description 8
- 102000013127 Vimentin Human genes 0.000 claims description 7
- 108010065472 Vimentin Proteins 0.000 claims description 7
- 235000013399 edible fruits Nutrition 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 235000015203 fruit juice Nutrition 0.000 claims description 6
- 210000005048 vimentin Anatomy 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 235000021559 Fruit Juice Concentrate Nutrition 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 7
- 238000001727 in vivo Methods 0.000 abstract description 5
- 231100000053 low toxicity Toxicity 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 238000012404 In vitro experiment Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 45
- 240000002547 Rosa roxburghii Species 0.000 description 26
- 235000000640 Rosa roxburghii Nutrition 0.000 description 26
- 239000000047 product Substances 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 241000282414 Homo sapiens Species 0.000 description 12
- 208000008443 pancreatic carcinoma Diseases 0.000 description 10
- 102000008186 Collagen Human genes 0.000 description 9
- 108010035532 Collagen Proteins 0.000 description 9
- 229920001436 collagen Polymers 0.000 description 9
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 8
- 201000002528 pancreatic cancer Diseases 0.000 description 8
- 239000006166 lysate Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 230000008021 deposition Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000621 bronchi Anatomy 0.000 description 3
- 210000003123 bronchiole Anatomy 0.000 description 3
- 238000005336 cracking Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000007790 scraping Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 210000000651 myofibroblast Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 210000003456 pulmonary alveoli Anatomy 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 201000004193 respiratory failure Diseases 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 206010001889 Alveolitis Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000011121 diffuse pulmonary fibrosis Diseases 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 1
- 229960004378 nintedanib Drugs 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960003073 pirfenidone Drugs 0.000 description 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/31—Extraction of the material involving untreated material, e.g. fruit juice or sap obtained from fresh plants
Abstract
The invention relates to application of roxburgh rose or extract thereof in preparation of a medicine or health-care product for preventing and treating pulmonary fibrosis, and belongs to the field of medicines or health-care products. The invention provides application of roxburgh rose or extract thereof in preparing a medicine or health-care product for preventing and treating pulmonary fibrosis. In vivo and in vitro experiments prove that the roxburgh rose can play an exact therapeutic role in pulmonary fibrosis, has low toxicity to normal renal cells and good safety. The application of the invention is beneficial to the prevention of pulmonary fibrosis, and provides a medicine or health care product with good curative effect, low toxicity and low price for patients with pulmonary fibrosis, and has obvious clinical and social significance.
Description
Technical Field
The invention relates to application of roxburgh rose or extract thereof in preparation of a medicine or health-care product for preventing and treating pulmonary fibrosis, and belongs to the field of medicines or health-care products.
Background
Pulmonary fibrosis (Lung fibrosis) is a chronic, progressive Lung injury or the result of Lung disease to an advanced stage. The lung cancer treating agent is characterized in that alveolitis and fibroblasts are proliferated in a large amount, extracellular matrix in lung tissues is accumulated and accompanied with inflammatory injury, an alveolus structure is damaged, and scar formation is caused by abnormal repair after the tissues are injured, so that the exchange of the lung and external gas is blocked, and finally respiratory failure and death are caused. The clinical symptoms of pulmonary fibrosis are mainly manifested by dyspnea, hypoxemia, dry cough and the like. With the factors such as the deterioration and pollution of the living environment of human beings, the incidence of pulmonary fibrosis is increased with the time, the prognosis is poor, the average survival period after diagnosis is short, and the mortality is high.
The pathogenesis of pulmonary fibrosis is currently unknown and can be caused by a variety of factors including smoking, age, environment, drugs, etc., which lead to inflammatory responses and oxidative damage, destruction of the normal architecture of alveolar basal cells, simultaneous release of a range of cytokines, stimulation of fibroblast to myofibroblast transformation and proliferation, collagen deposition and massive extracellular matrix formation, ultimately leading to irreversible pulmonary fibrosis.
The current clinical drugs for pulmonary fibrosis are mainly pirfenidone and nintedanib, but the treatment effect and safety are controversial, and the disease prognosis is not improved. The traditional treatment mode mainly aims at inhibiting inflammation, but long-term use of drugs such as glucocorticoid, immunosuppressant, cyclophosphamide and the like can cause liver and kidney injury, so that the immunity of the organism is reduced, new lesions or other diseases can be induced, the risk of respiratory failure is increased, and even serious secondary infection is caused to cause death. Therefore, the search for new pulmonary fibrosis prevention and treatment drugs is urgently needed.
Disclosure of Invention
The invention aims to provide application of roxburgh rose or extract thereof in preparing medicines or health-care products for preventing and treating pulmonary fibrosis.
The invention provides application of roxburgh rose or extract thereof in preparing a medicine or health-care product for preventing and treating pulmonary fibrosis.
The Rosa roxburghii is the fruit of Rosa roxburghii Tratt which is perennial deciduous shrub of Rosaceae.
Furthermore, the roxburgh rose adopts at least one of whole fruit, any part of fruit, fruit juice or fruit juice concentrate.
Further, the fruit juice is prepared by the following method: squeezing fresh fructus Rosae Normalis, and collecting liquid phase.
Preferably, the fruit juice is prepared by the following method: squeezing fresh fructus Rosae Normalis, filtering with gauze, and filtering with 0.22 μ M filter membrane.
Further, the pulmonary fibrosis is chemical induced pulmonary fibrosis.
Preferably, the pulmonary fibrosis is pulmonary fibrosis caused by bleomycin.
Further, the medicine or the health care product reduces the expression level of at least one of fibrosis-related proteins Vimentin and α -SMA in lung tissues.
Furthermore, the medicine or health care product inhibits the proliferation of fibroblasts and alveolar basal epithelial cells.
Further, the medicine or health product inhibits epithelial-mesenchymal transition.
Further, the medicine or the health care product reduces the expression of at least one of epithelial-mesenchymal transition-related protein α -SMA and Vimentin in alveolar basal epithelial cells.
Furthermore, the medicine or the health care product is a preparation prepared by taking the roxburgh rose or the extract thereof as an active ingredient and adding acceptable auxiliary materials or auxiliary ingredients.
Further, the preparation is an oral preparation, an injection preparation or an aerosol.
Further, the unit preparation contains 4 mL-8 mL of Rosa roxburghii juice. The unit preparation of the invention corresponds to the daily dosage of the human body per kg body weight.
The invention provides application of roxburgh rose or extract thereof in preparing a medicine or health-care product for preventing and treating pulmonary fibrosis. By establishing an in-vivo and in-vitro model, the invention proves that the roxburgh rose can play an exact therapeutic role in pulmonary fibrosis, has low toxicity to normal renal cells and good safety. The roxburgh rose is a third-generation fruit, most of which is still in a wild state and grows in a wild field without a pollution source; the source of the compound is wide, an industrial chain is formed at present, and the cost is low. The application of the invention is beneficial to the prevention of pulmonary fibrosis, and provides a medicine or health care product with good curative effect, low toxicity and low price for patients with pulmonary fibrosis, and has obvious clinical and social significance.
Drawings
FIG. 1 is a graph showing the survival rate of mouse embryonic fibroblasts in example 1;
FIG. 2 is a graph showing the survival rate of human alveolar basal epithelial cells of pancreatic cancer in example 1;
FIG. 3 is a graph of the effect of Rosa roxburghii juice on the morphological changes of TGF- β 1-stimulated A549 cells of example 1;
FIG. 4 is a graph showing the effect of Rosa roxburghii juice on the expression of proteins associated with epithelial-mesenchymal transition in A549 cells stimulated by TGF- β 1 in example 1;
FIG. 5 is a graph showing the change in expression of proteins associated with fibrosis of lung tissues of mice treated with Rosa roxburghii Tratt juice for 14 days in example 2;
FIG. 6 is a graph showing the effect of 14 days of treatment with Rosa roxburghii Tratt juice on lung pathology and collagen deposition changes in mice according to example 2;
FIG. 7 is a graph showing the survival rate of normal renal cells in example 3.
Detailed Description
The invention provides application of roxburgh rose or extract thereof in preparing a medicine or health-care product for preventing and treating pulmonary fibrosis.
The invention proves that the roxburgh rose can inhibit the proliferation of mouse embryonic fibroblast (NIH3T3) and pancreatic cancer human alveolar basal epithelial cells (A549) in a concentration and time-dependent mode, can obviously improve the expression change of epithelial mesenchymal transformation related proteins of the pancreatic cancer human alveolar basal epithelial cells (A549) caused by TGF- β 1 stimulation, enables α -SMA and Vimentin to be reduced, and animal experiments further prove that the roxburgh rose can obviously improve the pathological change range of lung of a pulmonary fibrosis mouse, relieves the damage of lung parenchymal structure, and has exact therapeutic effect on pulmonary fibrosis.
The scheme of the invention will be explained with reference to the examples. It will be appreciated by those skilled in the art that the following examples are illustrative of the invention only and should not be taken as limiting the scope of the invention. The examples, where specific techniques or conditions are not indicated, are to be construed according to the techniques or conditions described in the literature in the art or according to the product specifications. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products commercially available.
The roxburgh rose juice described in the following examples was prepared by the following method: squeezing fresh fructus Rosae Normalis, filtering with sterile gauze, filtering with 0.22 μ M filter membrane, and storing in refrigerator at-80 deg.C.
Example 1 in vitro cell experiment of Rosa roxburghii Tratt juice for preventing and treating pulmonary fibrosis
The hyperproliferation of mouse embryonic fibroblasts (NIH3T3) and pancreatic cancer human alveolar basal epithelial cells (A549) causes the deposition of collagen, and thus, the inhibition of their proliferation can inhibit the expression and deposition of collagen.
In the process of pulmonary fibrosis, TGF- β is a main fibrosis factor and can promote epithelial-mesenchymal transition (EMT) in vitro, inhibit apoptosis of fibroblasts and promote generation of active oxygen, and in vivo research also shows that a large amount of TGF- β release can accelerate the process of pulmonary fibrosis, A549 is stimulated by TGF- β 1 to accelerate the process of epithelial-mesenchymal transition (EMT) and further accelerate the formation of pulmonary fibrosis, so that the inhibition of the transformation of EMT can reduce the formation of pulmonary fibrosis.
The experiment proves the function of the roxburgh rose juice in preventing and treating pulmonary fibrosis from the two aspects.
1. Cell culture
Mouse embryo fibroblast (NIH3T3) and pancreatic cancer human alveolar basal epithelial cell (A549) are cultured in DMEM high-sugar medium containing 10% calf serum, 100U/mL penicillin and streptomycin are added into the culture medium in the cell culture and experiment process, and the culture is carried out at 37 ℃ and 5% CO2In an incubator.
2.MTT method for detecting influence of roxburgh rose juice on proliferation of two cells
Cells in logarithmic growth phase in the plate are taken, digested, counted, laid on a 96-well plate and cultured normally. Selecting cells with good state in logarithmic growth phase, inoculating a 96-well plate according to the growth speed of the cells, wherein each well has 100 mu L, the number of the cells is about 1500-4000, and normally culturing. The following day of inoculation, the final concentration of the diluted Rosa roxburghii Tratt juice was 0. mu.L/mL, 10. mu.L/mL, 20. mu.L/mL, 30. mu.L/mL, 40. mu.L/mL, 50. mu.L/mL, each concentration was 5-fold, and the mixture was placed at 37 ℃ in 5% CO2The incubators are respectively cultured for 24 hours, 48 hours and 72 hours. Then 20. mu.L of MTT stock solution of 5mg/mL was added to each well, the mixture was incubated in an incubator for 2 to 4 hours, the cell supernatant in the wells was gently aspirated from the edge, 150. mu.L of DMSO was added to each well, the mixture was placed on a horizontal shaker and shaken at 150r/min for 10min, and then the OD at 570nm was measured with a microplate reader. The experiment is repeated for three times, the data is collated, and the concentration and the growth inhibition rate of the roxburgh rose juice are calculated according to the absorbance value. The experimental results are shown in fig. 1 and fig. 2.
As can be seen from FIG. 1, the Rosa roxburghii juice can inhibit proliferation of mouse embryonic lung fibroblasts (NIH3T3) in a concentration and time dependent manner.
As can be seen from fig. 2, the rosa roxburghii tratt juice inhibited the proliferation of human alveolar basal epithelial cells (a549) of pancreatic cancer in a concentration and time dependent manner.
3. Determination of the Effect of Roxburgh rose juice on the morphological changes of human alveolar basal epithelial cells (A549) of pancreatic carcinoma after TGF- β 1 stimulation
Taking logarithmically growing cells, digesting, collecting the cells, removing supernatant, adding a fresh culture medium, blowing and mixing uniformly, measuring the cell density, uniformly inoculating the cells into a 6-pore plate, wherein each pore is 2mL of cell suspension, the density is that the control pore can grow fully after inoculating for 48 hours, after inoculating for 24 hours, starving the cells for 6 hours by using a serum-free culture medium, then stimulating the cells by using a completely fresh culture medium containing 5ng/mL of GF- β 1, after 1 hour, adding 40 mu L/mL of roxburgh rose juice, continuously culturing, adding the sample for 24 hours, taking out the 6-pore plate, and observing the change of cell morphology by using an inverted microscope under white light.
As can be seen from FIG. 3, TGF- β 1 stimulation causes the morphology of human pancreatic carcinoma alveolar basal epithelial cells (A549) to change from short spindle to long spindle, while Rosa roxburghii juice can inhibit the morphology change of A549 cells.
4. Testing the influence of Rosa roxburghii juice on the expression of EMT-transforming protein of human alveolar basal epithelial cells (A549) of pancreatic cancer after TGF- β 1 stimulation
The method comprises the steps of taking cells in a logarithmic growth phase, carrying out cell passage, ensuring that the density of passaged cells is 80-90% after 48 hours of a control group, dividing the cells into 4 dishes and 24 hours, starving the cells for 6 hours by using a serum-free culture medium, adding a completely fresh culture medium containing 5ng/mL of PLGF- β 1, stimulating the cells after 1 hour, adding 40 mu L/mL of rosa roxburghii tratt juice for intervention, continuously placing the cells into an incubator for culture after intervening for 24 hours, taking out the culture dish, placing the culture dish on ice for 10 minutes, discarding supernatant, gently washing the cells twice by using precooled PBS, adding 1mL of PBS to each dish, scraping the cells in a collection dish after cell scraping, centrifuging the cells for 3 minutes at 3000rpm for 4 ℃ after cell scraping the cells, washing for 2 times by precooled PBS, fully draining the supernatant, adding a proper amount of RIPA lysate, blowing and uniformly mixing the lysate with a transfer liquid gun, allowing the lysate to fully contact the cells, cracking the lysate with the cells, swirling the lysate once every 15min, cracking for 60min, allowing the lysate to be 60min, performing ultrasonic assisted cracking, allowing the lysate to be in a transparent lysis buffer solution, then 4 ℃, placing the PVDF membrane, performing a gel for a gel, performing a gel-.
As can be seen from FIG. 4, the TGF- β 1 stimulation leads to the up-regulation of the expression levels of human pancreatic cancer alveolar basal epithelial cell (A549) epithelial mesenchymal transition-related proteins α -SMA, Vimentin, and the Rosa roxburghii juice can inhibit the change.
Example 2 in vivo animal experiment of Rosa roxburghii Tratt juice for preventing and treating pulmonary fibrosis induced by bleomycin
Bleomycin (BLM) is an anti-squamous carcinoma drug, but causes pulmonary fibrosis. After bleomycin is instilled in bronchi, I-type alveolar epithelial cells are injured by inflammation to secrete proinflammatory factors, and the proliferation and differentiation of II-type epithelial cells can be observed on day 2, myofibroblasts are recruited, collagen is synthesized, extracellular matrix is accumulated, and tissue and interstitial fibrosis is caused. This is consistent with the induction of diffuse pulmonary fibrosis or fibro-alveolar inflammation in humans, suggesting that bleomycin-induced injury may provide a suitable model for this disease with unknown etiology and pathogenesis. Based on the results, a C57BL/6 mouse bleomycin-induced pulmonary fibrosis model (CNV) is established in the experiment, and the effect of the roxburgh rose juice on treating pulmonary fibrosis in vivo is evaluated.
(1) Anesthesia: 1% sodium pentobarbital, administered by intraperitoneal injection according to the weight of 55-60 mg/kg of a mouse.
(2) Preparation of the experiment: injector, surgical instruments and suture, iodophor, 2mg/kg bleomycin, normal saline and alcohol cotton.
(3) Experimental procedures and precautions:
1) mice were anesthetized by intraperitoneal injection.
2) After the mice are successfully anesthetized, the neck skin of the mice is cut by a sterile instrument, the bronchus is exposed, and other important tissues such as blood vessels of the mice cannot be damaged.
3) After finding the bronchus, injecting 2mg/kg/10mL of bleomycin by using an injector, taking care not to leak, slowly injecting all the bleomycin, then slowly pulling out the needle point, lifting the forelimb of the mouse by two hands, and uniformly shaking up, down, left and right to uniformly distribute the bleomycin in the lung.
4) The cut neck skin was then sutured with surgical sutures and sterilized by spraying iodophor.
5) After the molding is finished, the mouse is placed in a clean cage for resuscitation, the head of the mouse is slightly raised, the mouse is kept warm, the heartbeat and the breathing condition of the mouse are observed, and the asphyxia is prevented.
(4) Evaluation of the effect of the roxburgh rose juice against pulmonary fibrosis using the bleomycin model:
1) grouping experiments: bleomycin model group, Rosa roxburghii juice normal control group, Rosa roxburghii juice high and low dose group (8, 4mL/kg) and sham operation group.
2) The administration method comprises the following steps: the medicine is administered through oral gavage. The roxburgh rose juice high-low dose group is provided with corresponding dose of roxburgh rose juice after the model building, and the administration is started 24 hours after the model building, wherein the roxburgh rose juice is 4 mL/kg/day and 8 mL/kg/day for 14 days continuously. The model group was given the same dose of saline, otherwise known as the solvent group, as the high dose group after modeling. The normal Rosa roxburghii Tratt control group and the sham operation group are molded by normal saline with the same volume, the mice of the normal Rosa roxburghii Tratt control group are given 8 mL/kg/day of Rosa roxburghii Tratt juice, and the sham operation group is given normal saline with the same volume as that of the high-dosage group.
3) Evaluation indexes are as follows: after 14 days of administration, the state of the mice was observed, weighed and sacrificed, and lung tissues were taken out and soaked in formalin. Lung tissue was then paraffin embedded and sectioned. Measuring changes in expression of fibrosis-associated proteins in mouse lung tissue by western blotting; histopathological structures and collagen deposition status of mice were evaluated with HE staining and Masson staining. The experimental results are shown in fig. 5 and 6.
As shown in FIG. 5, the Western blot results showed that the Rosa roxburghii juice can inhibit the expression of the fibrosis-associated proteins α -SMA and Vimentin in lung tissue.
As shown in FIG. 6, H & E staining results show that the lung tissue structures of mice in the sham operation group and the rosa roxburghii tratt normal control group are complete and clear, the alveolar walls are not thickened, the alveolar cavities are transparent, no obvious exudation is seen in the cavities, no inflammatory cell infiltration is caused, and no fibroblast proliferation is caused. The pulmonary alveolar structure of the mice in the model group is damaged, the pulmonary alveolar space is widened, a large amount of inflammatory cells infiltrate, fibroblasts proliferate and pulmonary fibrosis is formed. Compared with the model group, the condition of the roxburgh rose juice high-dose group is improved, the range of pathological changes is obviously reduced, and the lung parenchyma structure is less damaged. The Masson staining results show that the lung tissue structures of mice in the sham operation group and the rosa roxburghii tratt normal control group are normal, a great amount of blue collagen fibers can be seen in the alveolar space, alveolar wall, and the periphery of the terminal bronchiole, respiratory bronchiole and bronchiole wall of mice in the fibrosis model group, and compared with the model group, the rosa roxburghii tratt juice high-dose group has light fibrosis degree and less total content of collagen.
The experimental results show that the roxburgh rose juice has the effects of reducing collagen fiber hyperplasia and improving pulmonary interstitial fibrosis.
Example 3 in vitro safety evaluation of Roxburgh rose juice
1. Culture of cells
Normal renal cells (VREO) were cultured in DMEM high-glucose medium containing 10% FBS, 100U/mL penicillin and streptomycin were added during the culture and experiment, and the culture was carried out at 37 deg.C and 5% CO2In an incubator.
MTT method for detecting influence of roxburgh rose juice on proliferation of normal renal cells (VREO)
Selecting cells with good logarithmic phase growth state, inoculating to 96-well plate according to cell growth speed, wherein each well contains about 1500-2000 cells, each well contains 100 μ L of cells, and the cells are cultured at 37 ℃ and 5% CO2Culturing in an incubator. Second inoculationDay, 100. mu.L of diluted solution of Sucus Rosae Normalis prepared with fresh medium was added to each well to give final concentration of 0. mu.L/mL, 10. mu.L/mL, 20. mu.L/mL, 30. mu.L/mL, 40. mu.L/mL, 50. mu.L/mL, 5 multiple wells at the same concentration, and 5% CO was added at 37 ℃ to each well2After 24, 48 and 72 hours of culture in an incubator respectively, 20 mu L of MTT stock solution is added into each hole, the mixture is put into the incubator to be cultured for 2 to 4 hours, cell supernatant is slightly sucked away, 150 mu L of DMSO is added into each hole, the mixture is placed on a horizontal shaking table to be shaken for 5 minutes at the speed of 150r/min, and an OD value is measured at the position of 570nm by a microplate reader. The experiment is repeated three times, the data is collated, and the growth inhibition rate and the concentration of the roxburgh rose juice are obtained according to the absorbance value. The results of the experiment are shown in FIG. 7.
As shown in FIG. 7, 50 μ M of the Rosa roxburghii juice had no significant proliferation inhibitory effect on normal renal cells (VREO) within 48h, and had some inhibitory effect on normal renal cells at 72h, but the toxicity was significantly less than that of other cells in the examples.
It should be appreciated that the particular features, structures, materials, or characteristics described in this specification may be combined in any suitable manner in any one or more embodiments. Furthermore, the various embodiments and features of the various embodiments described in this specification can be combined and combined by one skilled in the art without contradiction.
Claims (10)
1. Use of fructus Rosae Normalis or its extract in preparing medicine or health product for preventing and treating pulmonary fibrosis is provided.
2. Use according to claim 1, characterized in that: the roxburgh rose adopts at least one of whole fruit, any part of fruit, fruit juice or fruit juice concentrate.
3. Use according to claim 2, characterized in that: the fruit juice is prepared by the following method: juicing fresh fructus Rosae Normalis, and collecting liquid phase; preferably, the fruit juice is prepared by the following method: squeezing fresh fructus Rosae Normalis, filtering with gauze, and filtering with 0.22 μ M filter membrane.
4. Use according to claim 1, characterized in that: the pulmonary fibrosis is chemical pulmonary fibrosis; preferably, the pulmonary fibrosis is pulmonary fibrosis caused by bleomycin.
5. The method as set forth in claim 1, wherein the pharmaceutical or health product reduces the expression level of at least one of the fibrosis-associated proteins Vimentin, α -SMA in lung tissue.
6. Use according to claim 1, characterized in that: the medicine or health product can inhibit proliferation of fibroblast and alveolar basal epithelial cell.
7. The use according to claim 1, wherein the pharmaceutical or nutraceutical agent inhibits epithelial-to-mesenchymal transition, and further wherein the pharmaceutical or nutraceutical agent reduces the expression of at least one of the epithelial-to-mesenchymal transition-associated proteins α -SMA, Vimentin, in alveolar basal epithelial cells.
8. Use according to any one of claims 1 to 7, characterized in that: the medicine or health care product is a preparation prepared by taking roxburgh rose or extract thereof as an active ingredient and adding acceptable auxiliary materials or auxiliary ingredients.
9. Use according to claim 8, characterized in that: the preparation is an oral preparation, an injection preparation or an aerosol.
10. Use according to claim 8, characterized in that: the unit preparation contains 4 mL-8 mL of roxburgh rose juice.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911308961.8A CN110934911A (en) | 2019-12-18 | 2019-12-18 | Application of roxburgh rose or extract thereof in preparation of medicine or health-care product for preventing and treating pulmonary fibrosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911308961.8A CN110934911A (en) | 2019-12-18 | 2019-12-18 | Application of roxburgh rose or extract thereof in preparation of medicine or health-care product for preventing and treating pulmonary fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110934911A true CN110934911A (en) | 2020-03-31 |
Family
ID=69912004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911308961.8A Pending CN110934911A (en) | 2019-12-18 | 2019-12-18 | Application of roxburgh rose or extract thereof in preparation of medicine or health-care product for preventing and treating pulmonary fibrosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110934911A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113171373A (en) * | 2021-04-28 | 2021-07-27 | 河北科技师范学院 | Preparation method and application of avocado polysaccharide |
| CN114767748A (en) * | 2022-05-18 | 2022-07-22 | 中山大学 | Application of roxburgh rose or extract thereof in preparation of medicine or functional food for preventing and treating hepatic fibrosis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007186457A (en) * | 2006-01-13 | 2007-07-26 | Ichimaru Pharcos Co Ltd | Tryptase activity inhibitor and its utilization |
| CN110179786A (en) * | 2019-06-11 | 2019-08-30 | 四川大学 | The purposes of Galangin or its salt in the drug or health care product of preparation prevention and treatment pulmonary fibrosis |
-
2019
- 2019-12-18 CN CN201911308961.8A patent/CN110934911A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007186457A (en) * | 2006-01-13 | 2007-07-26 | Ichimaru Pharcos Co Ltd | Tryptase activity inhibitor and its utilization |
| CN110179786A (en) * | 2019-06-11 | 2019-08-30 | 四川大学 | The purposes of Galangin or its salt in the drug or health care product of preparation prevention and treatment pulmonary fibrosis |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113171373A (en) * | 2021-04-28 | 2021-07-27 | 河北科技师范学院 | Preparation method and application of avocado polysaccharide |
| CN114767748A (en) * | 2022-05-18 | 2022-07-22 | 中山大学 | Application of roxburgh rose or extract thereof in preparation of medicine or functional food for preventing and treating hepatic fibrosis |
| CN114767748B (en) * | 2022-05-18 | 2023-11-10 | 中山大学 | Application of roxburgh rose or extract thereof in preparation of medicine for preventing and treating liver fibrosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106074468B (en) | Cinnamic acid can induce the purposes in vegf expression and the inducer of secretion in preparation | |
| Liu et al. | Salidroside rescued mice from experimental sepsis through anti-inflammatory and anti-apoptosis effects | |
| CN110934911A (en) | Application of roxburgh rose or extract thereof in preparation of medicine or health-care product for preventing and treating pulmonary fibrosis | |
| CN111053800A (en) | Application of blueberries or extracts thereof in preparation of medicines or health-care products for preventing and treating pulmonary fibrosis | |
| CN110179786A (en) | The purposes of Galangin or its salt in the drug or health care product of preparation prevention and treatment pulmonary fibrosis | |
| Zhang et al. | Effects of panax notoginseng saponins on homing of C-kit+ bone mesenchymal stem cells to the infarction heart in rats | |
| Yang et al. | The protective effect of rhBNP on postresuscitation myocardial dysfunction in a rat cardiac arrest model | |
| CN109394749A (en) | The new application of Nifuroxazide or its salt | |
| US20220281916A1 (en) | Polypeptide and use thereof | |
| CN110251677B (en) | Pharmaceutical composition for treating pulmonary fibrosis and application thereof | |
| CN112402458A (en) | Application of mesenchymal stem cell and exosome combined preparation in preparation of myocardial infarction medicament | |
| CN115025137A (en) | External traditional Chinese medicine extract for promoting wound healing and extraction method and application thereof | |
| CN112891362B (en) | Pharmaceutical composition for treating sepsis and application thereof | |
| WO2021249402A1 (en) | Effects of cell-free fat liquid extract on macrophage polarization modulation and disease treatment | |
| CN114984219A (en) | Application of PD1 inhibitor in preparation of cardiac fibroblast transdifferentiation inhibitor | |
| CN114099534A (en) | Exosome of high-expression miR-214, preparation method and application thereof | |
| CN110960670B (en) | Application of phycocyanin peptide in preparation of anti-pulmonary fibrosis drugs | |
| CN114672456A (en) | Method for improving extracellular vesicle secretion efficiency of adipose-derived stem cells by utilizing ultrasonic stimulation and application | |
| CN107213455A (en) | A kind of stem cell medicine and its preparation method and application | |
| CN109395015B (en) | Application of rheumatism and pain relieving traditional Chinese medicine composition in preparation of anti-angiogenesis medicine | |
| Surtaieva et al. | Effects of transplanted mesenchymal stem cells on repair of the lung tissue of rats with experimental pulmonary fibrosis | |
| CN117106028B (en) | Protease activated peptide and application thereof in preparation of medicines for preventing and/or treating myocardial ischemia/reperfusion injury | |
| CN115569145B (en) | Application of polyguluronic acid propyl sulfate in preparation of products for preventing and treating atrial fibrillation | |
| CN108310015A (en) | Umbilical cord mesenchymal stem cells Cocktail treatment hyperglycemia and diabetic nephropathy | |
| CN108210518A (en) | Umbilical cord mesenchymal stem cells Cocktail treatment hyperglycemia and diabetic nephropathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200331 |